NEW YORK–(Organization WIRE)–#Action–Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights regulation company, is investigating probable statements from Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of lengthy-time period stockholders next a course motion criticism that was filed versus Athira on June 25, 2021 with a Class Period from September 17, 2020 to June 17, 2021. Our investigation considerations whether the board of directors of Athira have breached their fiduciary responsibilities to the firm.

On June 17, 2021, right after the sector shut, Athira declared that it experienced put its president and Main Executive Officer, Dr. Leen Kawas (“Kawas”), on go away pending a evaluate of actions stemming from doctoral investigate she done though at Washington Point out University (“WSU”).

The very same day, STAT posted an write-up stating that WSU was investigating claims that Dr. Kawas “published many papers that contains altered images even though she was a graduate university student.” These papers “are foundational to Athira’s attempts to address Alzheimer’s” due to the fact they “established that a distinct molecule affects the action of HGF.” However Athira is building a various molecule than the 1 Kawas examined in the papers at concern, her “doctoral do the job laid the biological groundwork that Athira proceeds to use in their technique to managing Alzheimer’s.”

The Registration Statement was materially wrong and misleading and omitted to point out: (1) that Kawas experienced published study papers made up of improperly altered illustrations or photos even though she was a graduate scholar (2) that this purported investigate was foundational to Athira’s efforts to establish solutions for Alzheimer’s since it laid the organic groundwork that Athira was making use of in its tactic to managing Alzheimer’s (3) that, as a final result, Athira’s intellectual home and merchandise enhancement for the treatment method of Alzheimer’s had been based on invalid research and (4) that, as a final result of the foregoing, Defendants’ positive statements about the Company’s organization, functions, and prospective customers, were materially deceptive and/or lacked a reasonable foundation.

If you are a extensive-term stockholder of Athira, have information, would like to learn far more about these claims, or have any inquiries relating to this announcement or your rights or interests with respect to these issues, please contact Brandon Walker or Alexandra B. Raymond by e-mail at [email protected], or phone at (212) 355-4648, or by filling out this get in touch with sort. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally identified regulation firm with workplaces in New York and California. The agency signifies particular person and institutional traders in commercial, securities, derivative, and other intricate litigation in state and federal courts across the state. For a lot more data about the company, you should visit Lawyer marketing. Prior final results do not warranty similar results.


Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Alexandra B. Raymond, Esq.

(212) 355-4648

[email protected]